Prothena Corporation PLC
NASDAQ:PRTA
Prothena Corporation PLC
Research & Development
Prothena Corporation PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Prothena Corporation PLC
NASDAQ:PRTA
|
Research & Development
-$134.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-9%
|
|
|
Alkermes Plc
NASDAQ:ALKS
|
Research & Development
-$318.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
|
Amarin Corporation PLC
NASDAQ:AMRN
|
Research & Development
-$19.8m
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
9%
|
|
|
M
|
Mural Oncology PLC
NASDAQ:MURA
|
Research & Development
-$110.7m
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Prothena Corporation PLC
Glance View
Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.
See Also
What is Prothena Corporation PLC's Research & Development?
Research & Development
-134.9m
USD
Based on the financial report for Dec 31, 2025, Prothena Corporation PLC's Research & Development amounts to -134.9m USD.
What is Prothena Corporation PLC's Research & Development growth rate?
Research & Development CAGR 10Y
-9%
Over the last year, the Research & Development growth was 39%.
